C. Hagenstad

发表

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Seta Shahin, J. Hecht, J. Marshall, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.

J. Nemunaitis, R. Hermann, J. Bendell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).

F. Kabbinavar, D. Slamon, J. Glaspy, 2010, Clinical breast cancer.

Cryptococcal aortitis presenting as a ruptured mycotic abdominal aortic aneurysm.

J. Deitch, G. Plonk, C. Hagenstad, 1999, Journal of vascular surgery.

A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC).

F. Greco, R. Birch, T. Goggins, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway

K. Kolibaba, F. Awan, Mitchell R. Smith, 2016 .

Inflammatory myofibroblastic tumor with bone marrow involvement. A case report and review of the literature.

S. Kilpatrick, M. Pettenati, C. Hagenstad, 2003, Archives of pathology & laboratory medicine.

Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.

D. Elashoff, R. Hermann, C. Vogel, 2009 .

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

L. Bosserman, D. Slamon, B. Childs, 2014, SpringerPlus.

Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

J. Nemunaitis, R. Hermann, J. Bendell, 2010 .

P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.

D. Amadori, R. Finn, T. Pintér, 2011 .

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.

L. Campos, C. Bedell, D. Richards, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.